Last reviewed · How we verify
NCT06226350
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
Phase 2 trial testing Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection in Cervical Cancer in 29 participants. Completed in 3 January 2024.
5 December 2023
Quick facts
| Lead sponsor | Shandong New Time Pharmaceutical Co., LTD |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 4 March 2021 |
| Primary completion | 5 December 2023 |
| Estimated completion | 3 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection — full drug profile →
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
Shandong New Time Pharmaceutical Co., LTD — full company profile →
Who can join
18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was an open, single-arm, enriched, multicenter Phase II study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov.
Zhou X, Xiao L, Lai F, Chen W, et al · · 2025 · cited 1× · PMID 40417700 · DOI 10.3389/fmed.2025.1521587
Verify or expand the search:
- PubMed search for NCT06226350
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Trials testing the same drug.
- NCT03657381 — Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 · Phase 1 · unknown
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other Shandong New Time Pharmaceutical Co., LTD trials
Trials by the same sponsor.
- NCT07046273 — Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes · Phase 3 · not yet recruiting
- NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06226363 — Phase I Study of LNF1901 in Advanced Malignant Tumors · Phase 1 · not yet recruiting
- NCT06206915 — Phase I Study of XZ120 in Malignant Tumors · Phase 1 · not yet recruiting
- NCT07396506 — Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06226350 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong New Time Pharmaceutical Co., LTD
- Last refreshed: 26 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06226350.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing